Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financi...(Present additional data from the complet...),Health

evaluate the effect of a single administration of SB-509 in subjects

with mild to moderate DN.

-- Complete follow-up and presentation of data in the second half of the

year from a Phase 2 study (SB-509-601) to evaluate the effects of

SB-509 in subjects with mild to moderate DN.

-- Complete accrual, follow-up and presentation of data from a Phase 2

study (SB-509-701) to evaluate SB-509 in subjects with moderate to

severe DN.

-- Complete accrual and treatment in the recently initiated Phase 2

pharmacokinetic trial (SB-509-703) to evaluate the effect of SB-509 on

stem cell mobilization

-- Initiate a Phase 2 clinical trial to evaluate SB-509 for the treatment

of ALS (Amyotrophic Lateral Sclerosis, also known as "Lou Gehrig's

disease").

-- Advance ZFP Therapeutic pipeline by initiating Phase 1 clinical trials

of ZFP Therapeutics for glioblastoma and HIV / CCR5.

-- Present preclinical data in spinal cord injury, stroke, neuropathic

pain and ZFN(TM)-mediated gene modification.

Business -- Strategic Collaborations & Enabling Technology Agreements

-- Pursue strategic partnering in ZFP Therapeutics.

-- Achieve additional research milestones in Dow AgroSciences

collaboration in plant agriculture.

-- Increase visibility and value of ZFNs by developing commercial

research reagents in collaboration with Sigma-Aldrich.

-- Establish new commercial license agreements using ZFNs to improve

cell-lines used in protein production and other biological

applications.

Financials and Operations

-- Maintain year-end 2008 cash and investments balance of at least $55.0

million.

Conference Call

Sangamo will host a conference call today at 5:00 p.m. ET, w
'/>"/>